IP Library Granted Patent US 7,622,437
Granted Patent B2
US 7,622,437 · App. 11/259,950 · Granted Nov 24, 2009

Tissue factor compositions and methods

Assignee: The Board of Trustees of the University of Illinois
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,622,437
App. No.
11/259,950
Granted
Nov 24, 2009
Kind
B2
Abstract

Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include supplementation in the case of a genetic deficiency, uncontrolled bleeding, surgical incisions or seepage, thrombocytopenia, soft tissue trauma or other trauma, to effect tumor regression or to inhibit tumor growth.

Claims (8)

1. A method for controlling bleeding in a human or animal patient, said method comprising the step of administering, in an amount effective to control bleeding in said patient a composition comprising nanoscale particles comprising tissue factor or recombinant tissue factor, a membrane scaffold protein and phospholipid, wherein the phospholipid comprises a net-negatively charged phospholipid, and wherein said nanoscale particles are attached to a solid support, whereby bleeding in said patient is controlled.

2. The method of claim 1 , wherein the phospholipid comprises from 1 to 50% on a molar basis of net-negative charged phospholipid and from 50 to 99% net-neutral phospholipid.

3. The method of claim 1 , wherein the phospholipid consists essentially of phosphatidylserine and phosphatidylcholine or phosphatidylserine and phosphatidylethanolamine in a molar ratio of 20:80 or consists essentially of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine in a molar ratio of 20:40:40.

4. The method of claim 1 , wherein the human or animal patient has hemophilia, a thrombocytopenia or other bleeding diathesis.

5. The method of claim 1 , wherein the patient has a surgical, wound or soft tissue trauma resulting in bleeding.

6. The method of claim 1 , wherein the solid support is a collagen containing material.

7. The method of claim 1 , wherein the membrane scaffold protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO: 4, SEQ ID NO:6, SEQ ID NO:8, amino acids 13-414 of SEQ ID NO:8, SEQ ID NO:10, amino acids 13-422 of SEQ ID NO:10, SEQ ID NO:12, amino acids 13-168 of SEQ ID NO:12, SEQ ID NO:14, amino acids 13-168 of SEQ ID NO:14, SEQ ID NO:16, amino acids 13-201 of SEQ ID NO:16, SEQ ID NO:17, amino acids 13-201 of SEQ ID NO:17, SEQ ID NO:18, amino acids 13-392 of SEQ ID NO:18, SEQ ID NO:50, amino acids 13-234 of SEQ ID NO:50, SEQ ID NO:51, amino acids 13-256 of SEQ ID NO:51, SEQ ID NO:52, amino acids 13-278 of SEQ ID NO:52, SEQ ID NO:53, amino acids 24-223 of SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, amino acids 24-212 of SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, amino acids 24-201 of SEQ ID NO:57, SEQ ID NO:58, amino acids 13-190 of SEQ ID NO:58, SEQ ID NO:59, amino acids 13-201 of SEQ ID NO:59, SEQ ID NO:60, amino acids 13-190 of SEQ ID NO:60, SEQ ID NO:61, amino acids 24-201 of SEQ ID NO:61, SEQ ID NO:62, amino acids 24-190 of SEQ ID NO:62, SEQ ID NO:63, amino acids 24-179 of SEQ ID NO:63, SEQ ID NO:64, amino acids 24-289 of SEQ ID NO:64, SEQ ID NO:65, amino acids 24-289 of SEQ ID NO:64, SEQ ID NO:65, amino acids 24-278 of SEQ ID NO:65, SEQ ID NO:66, amino acids 24-423 of SEQ ID NO:66, SEQ ID NO:67, amino acids 24-199 of SEQ ID NO:67, SEQ ID NO:68, amino acids 24-401 of SEQ ID NO:68, SEQ ID NO:69, amino acids 24-392 of SEQ ID NO:69, SEQ ID NO:81, amino acids 24-397 of SEQ ID NO:81, SEQ ID NO:83, amino acids 24-383 of SEQ ID NO:83, SEQ ID NO:85, amino acids 24-379 of SEQ ID NO:85, SEQ ID NO:87, amino acids 24-381 of SEQ ID NO:87, SEQ ID NO:89, amino acids 25-212 of SEQ ID NO:89, SEQ ID NO:91, amino acids 25-212 of SEQ ID NO:91, SEQ ID NO:93 and amino acids 13-212 of SEQ ID NO:93.

8. The method of claim 1 , wherein the tissue factor is a recombinant tissue factor consisting of amino acids 23 to 277 of SEQ ID NO:95.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 16, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024233/0943 →
CONFIRMATORY LICENSE Recorded Oct 29, 2008
From: UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021751/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2005
From: MORRISSEY, JAMES H.; PUREZA, VINCENT S.; SLIGAR, STEPHEN S.
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 016913/0985 →
Continuity (7)
Continuation In Part 1103348900 · Jan 11, 2005
Continuation In Part 1046578900 · Jun 18, 2003
Continuation In Part 0999008700 · Nov 20, 2001
Provisional Application 6062273700 · Oct 27, 2004
Provisional Application 6053628100 · Jan 13, 2004
Provisional Application 6025223300 · Nov 20, 2000
Related Publication 20060088524A1 · Apr 27, 2006